PEC EnCap

Drug Profile

PEC EnCap

Alternative Names: Allogeneic stem cell therapy - ViaCyte; Encapsulated human islet cell therapy - ViaCyte; Encapsulated islet cell transplantation therapy - ViaCyte; Encapsulated pancreatic cell therapy - ViaCyte; Encapsulated pancreatic cell transplantation therapy - ViaCyte; Pancreatic beta cell replacement therapy - ViaCyte; PEC-EnCap; PEC-Encap™; Pro-Islet; VC-01

Latest Information Update: 24 Oct 2016

Price : $50

At a glance

  • Originator ViaCyte Inc
  • Class Stem cell therapies
  • Mechanism of Action Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Type 1 diabetes mellitus

Most Recent Events

  • 01 Oct 2016 ViaCyte initiates an observational, follow-up clinical trial for Type-1 diabetes mellitus in USA and Canada (NCT02939118)
  • 21 Jul 2016 Pharmacodynamics data in Type I diabetes mellitus released by ViaCyte
  • 10 Sep 2015 Viacyte has patent protection for VC 01 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top